AlphAIalphai — Financial news for AI agents
benzinga.comJUN 183 min read$HIMSBullishMed

Hims & Hers Stock Jumps After Barclays Raises Price Target - Hims & Hers Health (NYSE:HIMS)

Barclays raised its price target for Hims & Hers Health, citing renewed strength in the GLP-1 segment. The report pointed to higher website traffic (up 12% YoY in April and 35% YoY in May) and Barclaycard data showing May transactions up 16% MoM and total spending up 14% MoM. Shares rose 9.94% to $35.06.

AI DeskJune 18, 2026
Source · benzinga.com
AI analysis
Relevance
7/10
Novelty
6/10
Actionability
Med
Sentiment · $HIMS
Bullish
Timing
today’s session after-hours/into next trading day following Barclays price-target raise
Market alignment
Bullish—analyst PT raise and constructive momentum (MACD above signal) align with the reported +9.94% move.
Why this matters for $HIMS

Analyst PT increase plus improving GLP-1 demand indicators are the immediate catalyst behind the stock’s ~10% jump.

Relevance context

Barclays raised its price target and cited Hims & Hers demand signals (site traffic +12% YoY in April, +35% in May) driving today’s rally.

Price-impact prediction

Near-term upside bias as traders follow the PT change, but resistance is flagged around $36.50.

Background

The piece frames Hims & Hers as rebounding from a difficult 12-month period (-42.39%) and trading around key moving-average levels after a December 2025 death-cross.

Why it matters

Barclays’ price-target raise is presented as the catalyst, supported by improving website traffic and transaction/spend trends tied to the GLP-1 segment; technical resistance/support levels suggest a near-term trading range.

Market relevance

Traders can use the PT change plus the cited demand proxies and the $36.50 resistance / $33.00 support levels to manage near-term momentum risk.

Market effects

Sector

Supports the read-through that GLP-1-related consumer demand is strengthening, which can buoy sentiment across weight-loss/telehealth names.

Regional

No explicit regional linkage beyond US-listed equity trading.

Global

Limited; the catalyst is analyst-driven and company-specific rather than a global macro shock.

Alternative perspectives

Contrarian view

The rally may be largely technical/positioning-driven; the article notes the stock is still under a death-cross regime and may face overhead supply near $36.50.

Overlooked factors

The demand signals are traffic/transaction/spend proxies; without confirmation of revenue/retention or guidance, the PT-driven move could fade if follow-on data disappoint.

Key entities

  • company
    Hims & Hers Health

    Subject of the article; shares rose ~9.94% to $35.06 as Barclays raised its price target and cited GLP-1 demand signals.

Read at source← All news

Related articles

JUN 23
$HIMSMed

Hims & Hers Health (NYSE: HIMS) Bets On GLP-1 Growth With Novo Nordisk Partnership And Eucalyptus Acquisition

Hims & Hers Health (HIMS) said it partnered with Novo Nordisk to add branded GLP-1 options, including Wegovy and Ozempic, for patients using its telehealth platform. The company also announced it will acquire Eucalyptus to expand internationally. Shares rose 41.2% in 30 days to $33.54, about 22.8% above an analyst consensus target of $27.32, according to the article.

foreignpolicyjournal.com4 min
JUN 16
$RGNTMedAI 8/10

Top Biotech Gainers: RGNT Withdraws F-1 Filing, FDA Clears CUPR's Maggot Therapy, MYO On Watch

Regentis (RGNT) shares rose 526.7% after it withdrew a planned SEC Form F-1 for a firm-commitment offering of 3.33M shares at an assumed $3.00. Cuprina (CUPR) jumped 111.8% after FDA clearance for MEDIFLY maggots for debridement of non-healing wounds. Intellia (NTLA) gained 23.2% on additional Phase 3 results for hereditary angioedema; it targets approval and a 1H 2027 launch.

rttnews.com6 min
MAY 26
$HIMSHighAI 9/10

Hims & Hers faces steep climb to hit 2026 guidance as Wegovy churn risk looms, says BofA

Bank of America said Hims & Hers faces a steep customer acquisition and churn challenge to meet its 2026 revenue guidance tied to its oral Wegovy subscription. Analysts estimate it must add ~225,000 new subscribers per quarter (Q2–Q4 2026) to hit the midpoint, with churn from a $39-to-$149 pricing step-up creating an ~$85M revenue headwind by Q4 2026. Under lower churn, the headwind is ~$25M. BofA reiterated Neutral and cut its price target to $25.

proactiveinvestors.com4 min